FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 311:1206-1211 November 8, 1984 Number 19 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

When aspirin is administered by mouth in low doses, poor systemic bioavailability may contribute to its apparent dose-related "selective inhibition" of thromboxane A2 formation. Systemic bioavailability of orally administered aspirin is necessary to inhibit prostacyclin synthesis by systemic vascular endothelium, whereas cumulative inhibition of thromboxane A2 formation by platelets may occur in the presystemic (portal) circulation. We simultaneously administered unlabeled aspirin orally and deuterium-labeled aspirin intravenously in five healthy volunteers. This permitted an estimation of the bioavailability of an oral dose from the ratio of plasma drug concentration-time curves for the labeled and the unlabeled species. Systemic bioavailability ranged from 46 to 51 per cent of single oral doses of 20, 40, 325, and 1300 mg of aspirin. Bioavailability was similar after single-dose and long-term oral administration of 325 mg. Thromboxane B2 formation in serum ex vivo after oral administration of 20 mg of unlabeled aspirin was reduced 39 per cent before aspirin was detected in the systemic circulation. Furthermore, incubation of simulated peak plasma aspirin concentrations in whole blood in vitro underestimated the inhibition of thromboxane B2 ex vivo after oral administration of 20 or 40 mg of unlabeled aspirin. These data are consistent with presystemic inhibition of platelets by aspirin and suggest that biochemical "selectivity" might be enhanced by slow administration of very low doses of aspirin, thereby optimizing conditions for cumulative, presystemic acetylation of platelet cyclooxygenase and inhibition of thromboxane formation.

This article has been cited by other articles:

• Patrono, C., Baigent, C., Hirsh, J., Roth, G. (2008). Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 199S-233S [Abstract] [Full Text]  
• Douketis, J. D., Berger, P. B., Dunn, A. S., Jaffer, A. K., Spyropoulos, A. C., Becker, R. C., Ansell, J. (2008). The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 299S-339S [Abstract] [Full Text]  
• FitzGerald, G. A. (2008). Summary. Arterioscler. Thromb. Vasc. Bio. 28: s51-s52 [Full Text]  
• Berger, J. S., Stebbins, A., Granger, C. B., Ohman, E. M., Armstrong, P. W., Van de Werf, F., White, H. D., Simes, R. J., Harrington, R. A., Califf, R. M., Peterson, E. D. (2008). Initial Aspirin Dose and Outcome Among ST-Elevation Myocardial Infarction Patients Treated With Fibrinolytic Therapy. Circulation 117: 192-199 [Abstract] [Full Text]  
• Capone, M. L., Tacconelli, S., Sciulli, M. G., Anzellotti, P., Di Francesco, L., Merciaro, G., Di Gregorio, P., Patrignani, P. (2007). Human Pharmacology of Naproxen Sodium. J. Pharmacol. Exp. Ther. 322: 453-460 [Abstract] [Full Text]  
• Gelbaya, T.A., Kyrgiou, M., Li, T.C., Stern, C., Nardo, L.G. (2007). Low-dose aspirin for in vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update 13: 357-364 [Abstract] [Full Text]  
• Campbell, C. L., Smyth, S., Montalescot, G., Steinhubl, S. R. (2007). Aspirin Dose for the Prevention of Cardiovascular Disease: A Systematic Review. JAMA 297: 2018-2024 [Abstract] [Full Text]  
• Undas, A., Brummel-Ziedins, K. E., Mann, K. G. (2007). Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 109: 2285-2292 [Abstract] [Full Text]  
• Clappers, N, Brouwer, M A, Verheugt, F W A (2007). Antiplatelet treatment for coronary heart disease. Heart 93: 258-265 [Full Text]  
• Fitzgerald, D. J., Maree, A. (2007). Aspirin and Clopidogrel Resistance. ASH Education Book 2007: 114-120 [Abstract] [Full Text]  
• Mitchell, J. A., Lucas, R., Vojnovic, I., Hasan, K., Pepper, J. R., Warner, T. D. (2006). Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J. 20: 2468-2475 [Abstract] [Full Text]  
• Cox, D., Maree, A. O., Dooley, M., Conroy, R., Byrne, M. F., Fitzgerald, D. J. (2006). Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers. Stroke 37: 2153-2158 [Abstract] [Full Text]  
• Harris, R. C., Breyer, M. D. (2006). Update on Cyclooxygenase-2 Inhibitors. CJASN 1: 236-245 [Abstract] [Full Text]  
• Patrono, C., Garcia Rodriguez, L. A., Landolfi, R., Baigent, C. (2005). Low-dose aspirin for the prevention of atherothrombosis.. NEJM 353: 2373-2383 [Full Text]  
• Corazzi, T., Leone, M., Maucci, R., Corazzi, L., Gresele, P. (2005). Direct and Irreversible Inhibition of Cyclooxygenase-1 by Nitroaspirin (NCX 4016). J. Pharmacol. Exp. Ther. 315: 1331-1337 [Abstract] [Full Text]  
• Williams, P. C., Coffey, M. J., Coles, B., Sanchez, S., Morrow, J. D., Cockcroft, J. R., Lewis, M. J., O'Donnell, V. B. (2005). In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets. Blood 106: 2737-2743 [Abstract] [Full Text]  
• Maree, A. O., Curtin, R. J., Dooley, M., Conroy, R. M., Crean, P., Cox, D., Fitzgerald, D. J. (2005). Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease. J Am Coll Cardiol 46: 1258-1263 [Abstract] [Full Text]  
• Capone, M. L., Sciulli, M. G., Tacconelli, S., Grana, M., Ricciotti, E., Renda, G., Di Gregorio, P., Merciaro, G., Patrignani, P. (2005). Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45: 1295-1301 [Abstract] [Full Text]  
• Steinhubl, S. R. (2005). The use of anti-inflammatory analgesics in the patient with cardiovascular disease: What a pain. J Am Coll Cardiol 45: 1302-1303 [Full Text]  
• Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., Roth, G. (2004). Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 234S-264S [Abstract] [Full Text]  
• van Ryn, J., Kink-Eiband, M., Kuritsch, I., Feifel, U., Hanft, G., Wallenstein, G., Trummlitz, G., Pairet, M. (2004). Meloxicam Does Not Affect the Antiplatelet Effect of Aspirin in Healthy Male and Female Volunteers. J Clin Pharmacol 44: 777-784 [Abstract] [Full Text]  
• O'Kane, P. D., Queen, L. R., Ji, Y., Reebye, V., Stratton, P., Jackson, G., Ferro, A. (2003). Aspirin modifies nitric oxide synthase activity in platelets: effects of acute versus chronic aspirin treatment. Cardiovasc Res 59: 152-159 [Abstract] [Full Text]  
• Eidelman, R. S., Lamas, G. A., Hennekens, C. H., Ridker, P. M. (2002). Aspirin, Postmenopausal Hormones, and C-Reactive Protein. Arch Intern Med 162: 480-481 [Full Text]  
• Catella-Lawson, F., Reilly, M. P., Kapoor, S. C., Cucchiara, A. J., DeMarco, S., Tournier, B., Vyas, S. N., FitzGerald, G. A. (2001). Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin. NEJM 345: 1809-1817 [Abstract] [Full Text]  
• Ouellet, M., Riendeau, D., Percival, M. D. (2001). A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc. Natl. Acad. Sci. USA 10.1073/pnas.251543298v1 [Abstract] [Full Text]  
• Patrono, C., Coller, B., Dalen, J. E., FitzGerald, G. A., Fuster, V., Gent, M., Hirsh, J., Roth, G. (2001). Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects. Chest 119: 39S-63S [Full Text]  
• Pratico, D., Cyrus, T., Li, H., FitzGerald, G. A. (2000). Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. Blood 96: 3823-3826 [Abstract] [Full Text]  
• Awtry, E. H., Loscalzo, J. (2000). Aspirin. Circulation 101: 1206-1218 [Full Text]  
• McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., FitzGerald, G. A. (1999). Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. USA 96: 272-277 [Abstract] [Full Text]  
• Cullen, L., Kelly, L., Connor, S. O., Fitzgerald, D. J. (1998). Selective Cyclooxygenase-2 Inhibition by Nimesulide in Man. J. Pharmacol. Exp. Ther. 287: 578-582 [Abstract] [Full Text]  
• Huang, C., Ma, W.-Y., Hanenberger, D., Cleary, M. P., Bowden, G. T., Dong, Z. (1997). Inhibition of Ultraviolet B-induced Activator Protein-1 (AP-1) Activity by Aspirin in AP-1-Luciferase Transgenic Mice. J. Biol. Chem. 272: 26325-26331 [Abstract] [Full Text]  
• (1997). Which prophylactic aspirin?. DTB 35: 7-8 [Abstract] [Full Text]  
• Lopez-Farre, A., Caramelo, C., Esteban, A., Alberola, M. L., Millas, I., Monton, M., Casado, S. (1995). Effects of Aspirin on Platelet-Neutrophil Interactions : Role of Nitric Oxide and Endothelin-1. Circulation 91: 2080-2088 [Abstract] [Full Text]  
• Patrono, C. (1994). Aspirin as an Antiplatelet Drug. NEJM 330: 1287-1294 [Full Text]  
• Ware, J. A., Heistad, D. D. (1993). Platelet-Endothelium Interactions. NEJM 328: 628-635 [Full Text]  
• Ouellet, M., Riendeau, D., Percival, M. D. (2001). A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin. Proc. Natl. Acad. Sci. USA 98: 14583-14588 [Abstract] [Full Text]